Scholarlink

Introduction <p>The EF-BI study, a nationwide observational and retrospective study conducted in France, found better insulin persistence, fewer insulin therapy-related acute hospitalizations, and lower healthcare costs in adults with Type 2 diabetes (T2D) who initiated treatment with insulin glargine 300&#xa0;U/mL (Gla-300) compared to those who started on insulin glargine 100&#xa0;U/mL (Gla-100) over a 3-year follow-up period. Given the heterogeneity of the T2D population, the benefits observed may vary according to individuals’ characteristics. A post hoc analysis of this study was conducted to verify whether these findings were consistent in all age groups, including the elderly population.</p> Methods <p>Using the French national health insurance information system, adults with T2D who initiated basal insulin therapy with Gla-300 or Gla-100 between January 1, 2016, and December 31, 2020, and had no prior insulin use in the previous 6 months, were selected. Covariate adjustment using a propensity score based on key individuals’ characteristics was applied to estimate outcomes and costs between the two basal insulins. Analyses were conducted using several age cut-offs (65, 75, and 80 years).</p> Results <p>Overall, 235,894 people with T2D were included: 175,537 initiated treatments with Gla-100 and 60,357 with Gla-300. Across both age groups (&lt;&#xa0;65 years or older), treatment with Gla-300 was associated with better persistence and a lower frequency of acute insulin-related events. Cost comparisons per individual treated over 3&#xa0;years showed significant results favoring Gla-300:—&#xa0;€2,031 (−&#xa0;7.3%, <i>p</i>&#xa0;&lt;&#xa0;0.0001) in the&#xa0;&lt;&#xa0;65 years group, and—&#xa0;€2,914 (−&#xa0;7%, <i>p</i>&#xa0;&lt;&#xa0;0.0001) in the older group.</p> Conclusion <p>This EF-BI post hoc analysis found that Gla-300 was associated with lower overall costs, better persistence, and fewer insulin-related acute events compared to Gla-100 in several age subgroups in people with T2D in France. Further investigations are needed to confirm these results, including glycemic control and comparison with other second-generation basal insulins</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficiency of Gla-300 versus Gla-100 Across Age Groups in People Living with Type 2 Diabetes in France: A Post Hoc Analysis of an Observational Longitudinal Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月9日

查看全文
  • Patrice Darmon,
  • Olivier Hanon,
  • Pierre Gourdy,
  • Isabelle Borget,
  • Bruno Detournay,
  • Pierre Evenou,
  • Isabelle Bureau,
  • Noemie Allali,
  • Aymeric Mahieu,
  • Corinne Emery,
  • Alfred Penfornis

摘要

Introduction

The EF-BI study, a nationwide observational and retrospective study conducted in France, found better insulin persistence, fewer insulin therapy-related acute hospitalizations, and lower healthcare costs in adults with Type 2 diabetes (T2D) who initiated treatment with insulin glargine 300 U/mL (Gla-300) compared to those who started on insulin glargine 100 U/mL (Gla-100) over a 3-year follow-up period. Given the heterogeneity of the T2D population, the benefits observed may vary according to individuals’ characteristics. A post hoc analysis of this study was conducted to verify whether these findings were consistent in all age groups, including the elderly population.

Methods

Using the French national health insurance information system, adults with T2D who initiated basal insulin therapy with Gla-300 or Gla-100 between January 1, 2016, and December 31, 2020, and had no prior insulin use in the previous 6 months, were selected. Covariate adjustment using a propensity score based on key individuals’ characteristics was applied to estimate outcomes and costs between the two basal insulins. Analyses were conducted using several age cut-offs (65, 75, and 80 years).

Results

Overall, 235,894 people with T2D were included: 175,537 initiated treatments with Gla-100 and 60,357 with Gla-300. Across both age groups (< 65 years or older), treatment with Gla-300 was associated with better persistence and a lower frequency of acute insulin-related events. Cost comparisons per individual treated over 3 years showed significant results favoring Gla-300:— €2,031 (− 7.3%, p < 0.0001) in the < 65 years group, and— €2,914 (− 7%, p < 0.0001) in the older group.

Conclusion

This EF-BI post hoc analysis found that Gla-300 was associated with lower overall costs, better persistence, and fewer insulin-related acute events compared to Gla-100 in several age subgroups in people with T2D in France. Further investigations are needed to confirm these results, including glycemic control and comparison with other second-generation basal insulins